Compare AOSL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AOSL | SGMT |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.5M | 676.3M |
| IPO Year | 2007 | 2021 |
| Metric | AOSL | SGMT |
|---|---|---|
| Price | $24.76 | $10.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $24.00 | ★ $26.13 |
| AVG Volume (30 Days) | 518.8K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,291,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.01 | $4.50 |
| 52 Week High | $54.34 | $11.45 |
| Indicator | AOSL | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 37.60 | 61.77 |
| Support Level | $19.92 | $6.60 |
| Resistance Level | $37.00 | $11.15 |
| Average True Range (ATR) | 0.98 | 0.51 |
| MACD | 0.27 | -0.08 |
| Stochastic Oscillator | 23.97 | 56.18 |
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.